Download - Terapia biologica dislipidemias
![Page 1: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/1.jpg)
+
TERAPIA BIOLOGICA: DISLIPIDEMIAS
![Page 2: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/2.jpg)
+TRATAMIENTOS DIRIGIDOS, EN DONDE SE USAN FARMACOS QUE ESTAN ESPECIALMENTE DISEÑADOS PARA ESTIMULAR O INHIBIR EL SISTEMA INMUNITARIO
The New England Journal of Medicine “Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol”Pag. 1108
![Page 3: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/3.jpg)
+MÉTODO: DISEÑO DEL ESTUDIO
TRES ESTUDIOS SEPARADOS DE REGN727:
The New England Journal of Medicine “Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol”Pag. 1108
![Page 4: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/4.jpg)
+ESTUDIOS DE DOSIS ÚNICA 40 SUJETOS IV REGN727
32 SUJETOS SC REGN727
CRITERIOS DE INCLUSIÓN:
The New England Journal of Medicine “Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol”Pag. 1108 - 1111
![Page 5: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/5.jpg)
+ADMINISTRACIÓN INTRAVENOSA
ADMINISTRACIÓN SUBCUTÁNEA
The New England Journal of Medicine “Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol”Pag. 1109
![Page 6: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/6.jpg)
+
COMO VALORACIÓN DE SEGURIDAD EN ESTOS DÍAS TAMBIÉN SE EVALUÓ:
EVALUACIÓN DE NIVELES SÉRICOS DE LÍPIDOS AL INICIO Y A LOS DÍAS 1, 2, 4, 8, 11, 15, 22, 29, 43, 64, 85 Y 106
The New England Journal of Medicine “Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol”Pag. 1110
![Page 7: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/7.jpg)
+ESTUDIO DE DOSIS MÚLTIPLE
ATORVASTATINALDL >130mg/dl
The New England Journal of Medicine “Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol”Pag. 1110
![Page 8: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/8.jpg)
+ADMINISTRACIÓN SUBCUTÁNEA
291 43
![Page 9: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/9.jpg)
+EFECTOS ADVERSOS
The New England Journal of Medicine “Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol”Pag. 1111
EA: CEFALEANINGÚN PCTE
DESCONTINUO EL TRATAMIENTO POR
ALGUN TIPO DE EFECTO ADVERSO
![Page 10: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/10.jpg)
+
![Page 11: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/11.jpg)
+
![Page 12: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/12.jpg)
+
![Page 13: Terapia biologica dislipidemias](https://reader036.vdocuments.pub/reader036/viewer/2022062307/555cc59fd8b42a5f718b53a9/html5/thumbnails/13.jpg)
+